Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
A federal court jury found that the companies did not mislead a Louisiana man and his doctors about the health risks of the Xarelto blood thinner.
A supplemental new drug application has been filed by Janssen seeking to update the prescribing information for Xarelto, or r -More-
Johnson & Johnson unit Janssen Research & Development's supplemental new drug application for a 10-mg daily dose of Xarelto, -More-
Bayer and Johnson & Johnson have won the first of around 18,000 lawsuits lawsuit being brought by US patients who claim the blood-thinning drug Xarelto caused their uncontrollable brain and gastro...
A federal court in New Orleans, Louisiana, has cleared manufacturer Bayer and its US marketing partner Johnson & Johnson of liability in the second trial of what is expected to be more than 18,000...
A former Bayer sales rep says he was forced to gather patient data that was used to prepare medical journal papers for promoting the Xarelto blood thinner.
DelveInsight's, Xarelto API Insights, 2017 report provides product and API manufacturers details across the globe along with the location. The report gives the clear idea on the country wise DMF file...
(Reuters) - A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the first trial to flow out of thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drugmakers...
Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...